Aurora Mobile (NASDAQ:JG) reported quarterly sales of $12.60 million which beat the analyst consensus estimate of $12.32 million by 2.28 percent. This is a 20.65 percent decrease over sales of $15.88 million the same
Accelerated FDA approval for Eli Lilly's selpercatinib (Retevmo) in pediatric patients aged 2+ with advanced/metastatic thyroid cancer & solid tumors carrying RET mutations or fusions.